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Background. The need for a high level of adherence to antiretroviral drugs has remained a major hurdle to achieving maximal
beneﬁt from its use in pregnancy. This study was designed to determine the level of adherence and identify factors that inﬂuence
adherence during pregnancy. Method. This is a cross-sectional study utilizing a semistructured questionnaire. Bivariate and
multiple logistic regression models were used to determine factors independently associated with good drug adherence during
pregnancy. Result. 137 (80.6%) of the interviewed 170 women achieved adherence level of ≥95% using 3 day recall. The desire
to protect the unborn child was the greatest motivation (51.8%) for good adherence. Fear of being identiﬁed as HIV positive
(63.6%) was the most common reason for nonadherence. Marital status, disclosure of HIV status, good knowledge of ART, and
having a treatment supporter were found to be signiﬁcantly associated with good adherence at bivariate analysis. However, after
controlling for confounders, only HIV status disclosure and having a treatment partner retained their association with good
adherence. Conclusion. Disclosure of HIV status and having treatment support are associated with good adherence. Maternal
desire to protect the child was the greatest motivator for adherence.
1.Introduction
The introduction of highly active antiretroviral therapy
(HAART) has not only improved longevity in HIV-infected
individuals but in addition has had a signiﬁcant impact on
the rate of mother-to-child transmission of HIV infection
(MTCT) [1]. Mother-to-child transmission is one of the
modesofHIVtransmission.Vaginaldeliverycontributes60–
70% of MTCT, breastfeeding contributes 20–30%, while in-
utero infection could occur in less than 10% of MTCT [2].
Without preventive intervention, about 25–40% of infants
born to HIV-positive mothers will contract the virus [2].
Following introduction of HAART, the rates of mother-to-
childtransmissionofHIVinfectionhaspracticallycrashedto
less than 2% [3, 4]. However, the success of HAART, like any
medication, is dependent on both the intrinsic properties of
the drugs and the individual’s ability to take the medication
as prescribed [5]. This is particularly true in the prevention
of mother-to-child transmission, where the consequence of
failing to achieve viral suppression is the transmission of the
virus to the baby [5]. Adequate adherence to the prescribed
antiretroviral medications is essential to achieving maximal
viral suppression necessary to prevent MTCT [4].
Adherence rates exceeding 95% are necessary, in order to
maximize the beneﬁts of antiretroviral therapy. Higher levels
of drug adherence are associated with improved virological,
immunological, and clinical outcome [6].
Poor adherence to antiretroviral drugs during pregnancy
can lead to suboptimal viral suppression, development of
viral resistance, higher risk of mother-to-child transmission,
and mother-to-child transmission of resistant HIV strains
[5].
Interruptingmedicationpermitsthevirustoresumerap-
id replication and as many as 1010 viral particles will be pro-
duced per day [7].
This allows resistant mutant strains to be generated
which are no longer responsive to available antiretroviral
drugs, posing a public health danger [7].
Adherence to antiretroviral drugs poses unique challen-
ges to HIV infected persons particularly in pregnant women2 Journal of Pregnancy
[7]. Improving adherence among pregnant women therefore
requires knowledge of the factors that inﬂuence adherence.
Several methods have been used to measure adherence,
but no gold standard has been established [8]. Each of these
methods has its respective strengths and weaknesses. Avail-
able methods include pill counts, self-report, prescription
reﬁlls, medication event monitoring system (MEMS), bio-
logical markers, and assays [4, 9].
Though several studies in Nigeria have evaluated the
factors associated with nonadherence to antiretroviral ther-
apy among HIV-positive adults [10–12], only one from
literature search studied antiretroviral adherence issues in
HIV-positive pregnant women [4].
They deduced from their study that the determinants of
nonadherence to antiretroviral drugs in HIV-positive preg-
nant women were low level of education, nondisclosure of
HIV status, and longer duration of therapy [4].
Good adherence is imperative for the success of PMTCT.
This study, therefore, seeks to ﬁnd out if there is good adher-
ence to antiretroviral drugs among HIV-positive pregnant
women.
The main objective of this study is to determine the level
and factors that inﬂuence adherence to antiretroviral drugs
among HIV-positive pregnant women accessing PMTCT
services in Lagos Nigeria.
Research Questions
(1) What is the level of adherence to antiretroviral drugs
among pregnant women?
(2) What are the barriers to adherence in pregnancy?
(3) What factors facilitate adherence among pregnant
women?
2. Method
2.1.StudySetting. ThestudywasconductedattheHIVtreat-
ment Centre of the Nigerian Institute of Medical Research
(NIMR), Lagos, a Federal Government of Nigeria Compre-
hensive HIV Care and Treatment Centre. NIMR is supported
by AIDS Prevention Initiative in Nigeria (APIN) through
the United States president’s emergency fund for AIDS relief
(PEPFAR), funding since 2004. The Centre provides an
outpatient Prevention of Mother-To-Child-Transmission of
HIV Infection (PMTCT) services, in addition to adult and
pediatric HIV services. Pregnant women who tested positive
to HIV are referred from the NIMR HIV counseling and
testing centre or other public and private health institutions
to the PMTCT clinic which takes place once a week, on
Wednesdays. Intrapartum care is provided for these women
incollaborationwithsomehospitalswithinLagosmetropolis
which include Lagos University Teaching Hospital Idi Araba,
Lagos State University Teaching Hospital Ikeja, General
HospitalSurulere,GeneralHospital Apapa,GeneralHospital
Ikorodu, Havana Specialist Hospital Surulere, and Rao
Specialist Hospital Surulere. Antenatal, postnatal, and infant
post exposure prophylaxes are provided by NIMR. Health
workers from the collaborating centres have been trained on
intrapartum care of HIV-positive mothers both by NIMR
and the national HIV programme. Each woman on the
PMTCT programme is referred to any of the collaborating
centres, close to their place of residence at 36 weeks or as
soon as possible for late booking. The referral note usually
contains detailed information about their chosen mode of
delivery, infant feeding choice, client’s Viral Load, and CD4
count. Infant postexposure prophylaxis drugs and mother’s
antiretroviral drugs are given to the women on referral. The
women are sent back to the centre at 2 weeks postdelivery
with a completed Case Record Form (CRF) designed speciﬁ-
cally to capture all delivery-related information. Information
on the CRF is used to complete the postnatal data base. The
Home-Based Care Team contacts any of the women who did
not report back 2 weeks after the expected date of delivery.
This is to ascertain the reasons for the default.
2.2. Study Design. This is a cross-sectional study that was
carried out between 1st September 2009 and 31st November
2009. A semistructured questionnaire was administered to
the women who met the inclusion criteria and gave consent
to participate in the study. Knowledge of ART was measured
by asking some basic questions, which were graded. A score
above 70% was classiﬁed good while below 70% was not
good. Adherence was measured by expressing the number
of doses taken as a percentage of the number of doses
prescribed. For example if 20 doses are prescribed and 19
doses are taken, adherence is 95% [13].
2.3. Study Population. All pregnant women with known
gestational age either by date or early ultrasound seen during
the study period and who gave informed consent were
enrolled.Atthetimeoftheconductofthestudy,atotalof273
pregnant HIV-positive women were registered for PMTCT
services. The study aimed for a precision of ±5% for a
proportion of 50% using 95% conﬁdence interval, therefore,
a sample size of 70 subjects was required. In order to increase
thepowerofthestudy,wedecidedtoenrollallpregnantHIV-
positive women who attended PMTCT clinic between 1st
September and 31st November 2009 provided the minimum
sample size of 70 is met.
2.4. Data Management. The enrolled women were inter-
viewed using a semistructured questionnaire containing
closedandopen-endedquestions.Theopen-endedquestions
were included to give the women opportunity to freely
express themselves without boxing them into closed answers.
Information on demographics, socioeconomic characteris-
tics, knowledge of HIV, and antiretroviral drug medication,
adherence pattern, reasons for missing drugs, and factors
that encourage adherence were also contained in the ques-
tionnaire. Data management was with SPSS for windows
version 17. The P value was based on 95% conﬁdence
intervals (CI); a P value > 0.05 was not signiﬁcant (NS).
Descriptive analyses were ﬁrst performed followed by
bivariate analyses of the determinant factors associated with
good adherence. The variables that were found signiﬁcant
at this level were added to a multivariate logistic regression
model and those with a P-value < 0.05 were consideredJournal of Pregnancy 3
signiﬁcant in the ﬁnal multivariate model, calculating odds
ratios (OR) and 95% conﬁdence interval (CI).
2.5. Ethical Issues. Ethical approval for the study was ob-
tained from the Institutional Review Board, Nigerian Insti-
tute of Medical Research, Lagos, Nigeria. Written informed
consent was obtained from all women for the use of their
data for study however, women who declined consent to
participate in study were provided care but excluded from
research.
The clinic patients are organized into an independent
support group of people living with HIV (Positive Life
Organization of Nigeria) that ensures that patients are not
stigmatized and discriminated against. This group ensures
that no patient is denied requisite care because of failure to
participate in any of our studies including this study.
3. Results
Duringthethreemonthsstudyperiod,onehundredandsev-
enty eligible HIV-positive pregnant women consented and
were interviewed. One hundred and thirty seven (80.6%) of
the interviewed women reported achieving adherence level
of greater or equal to 95% using 3 day recall method, with a
nonadherent rate of 19.4%.
The sociodemographic characteristics of the respondents
are shown in Table 1. Majority of the women were aged
30–34 years (52.4%), married (77.1%), have at least one
livingchild(70.0%),employed/working(76.5%),hadatleast
secondary education (81.1%), and from the three major
ethnic tribes of Yoruba, Igbo, and Hausa (84.1%).
Pregnancy and HIV-related characteristics are summa-
rized in Table 2. One hundred and forty seven (86.5%)
women had disclosed their HIV status and their disclosure
was to their partners in most of the cases (97.3%). The
majority of the women were on ﬁrst line HAART regimen
(58.2%), while the rest of the women were either on non-
HAART prophylactic regimen (24.7%) or 2nd line HAART
regimen (17.1%). Only 20.0% and 22.9% of the women
have had previous PMTCT experience and were within the
ﬁrst trimester, respectively. Their knowledge of HIV and
antiretroviral therapy were very good as over 85% of the
respondent had very good knowledge. The use of treatment
support was relatively common as greater than half of the
women had a treatment supporter (55.9%) who is the
husband in 89.5% of the cases.
Theoutcomeofsubanalysisofreasonsgivenforadhering
to the antiretroviral drugs as prescribed, among the women
that had adherence level greater 95%, is shown in Table 3.
The desire to ensure that the unborn child is protected from
HIV infection was the greatest motivation (51.8%). Some of
the written expression of the women, expressing the desire to
protect the child as the motivation for adherence includes “I
want to protect my baby,” “I do not want to live with the guilt of
infecting my baby,” and “I learnt my baby will not be infected
if I take my drugs religiously.” The desire to remain healthy
and alive was the other motivator for adhering to the ARV
drugs (21.2%). These are some of the respondents’ written
expression “Iw a n tt ol i v el o n gt r a i nm yc h i l d r e na n df u l ﬁ l lm y
Table 1: The sociodemographic characteristics of the women en-
rolled in the study.
Characteristics Number of women (%)
N = 170
Age (years)
(i) <20 2 (1.2)
(ii) 20–24 20 (11.8)
(iii) 25–29 43 (25.3)
(iv) 30–34 89 (52.4)
(v) 35–39 13 (7.6)
(vi) ≥40 3 (1.8)
Number of living children
(i) 0 51 (30.0)
(ii) 1–2 67 (39.4)
(iii) >2 52 (30.6)
Marital status
(i) Married 131 (77.1)
(ii) Not married 39 (22.9)
Occupation
(i) Housewife 35 (20.6)
(ii) Unemployed 5 (2.9)
(iii) Employed/Working 130 (76.5)
Educational level completed
( i )N of o r m a le d u c a t i o n 3( 1 . 8 )
(ii) primary 29 (17.1)
(iii) Secondary 99 (58.2)
(iv) Tertiary 39 (22.9)
Ethnic group
(i) Yoruba 78 (45.9)
(ii) Igbo 52 (30.6)
(iii) Hausa 13 (7.6)
(iv) Other tribes 27 (15.9)
life dreams,” “To keep me healthy, as I was always on admission
in the hospital before I started treatment. I am now okay since
I started the ARV drugs.”
The reasons given by the nonadherent respondents for
missing or skipping their drugs are shown in Table 4.
Forgetfulness (57.6%), tight work schedule (39.4%), and
fear of being identiﬁed as HIV positive (63.6%) were the
common reasons for skipping or missing drugs among the
nonadherent women. The respondents expressed this in
written form, for example, “I get stuck in traﬃc sometimes on
my way home from work and am not comfortable carrying my
drugs around or taking them in the public.”
Table 5 shows the bivariate analysis of some possible
factors associated with good drug adherence. Of the nine
variables, only four variables which are marital status (P =
0.023), disclosure of HIV status (P = 0.000), good knowl-
edge of HIV, and ART (P = 0.001 and having a treatment
supporter (0.002) were found to be signiﬁcantly associated
with good adherence. However, after subjecting the variables
found to be signiﬁcantly associated with good adherence
to multiple logistic regressions while controlling for other4 Journal of Pregnancy
Table 2: The distribution of pregnancy and HIV related character-
istics of the women enrolled in the study.
Characteristics Number of women (%)
N = 170
HIV status disclosure
(i) Disclosed 147 (86.5)
(ii) Not disclosed 23 (13.5)
ARV drug regimen
(i) Mono and Dual therapy 42 (24.7)
(ii) First line HAART 99 (58.2)
(iii) 2nd line HAART 29 (17.1)
Gestational age (weeks)
(i) Less than 13 39 (22.9)
(ii) 13–28 52 (30.6)
(iii) Greater or equal to 29 79 (46.5)
Previous PMTCT experience
(i) Yes 34 (20.0)
(ii) No 136 (80.0)
Knowledge of HIV and ART
(i) Good 146 (85.9)
(ii) Poor 24 (14.1)
Has treatment supporter
Yes 95 (55.9)
No 75 (44.1)
Table 3: Reason for adherence to ARV drugs among respondents
with over 95% drug adherence.
Reason for Adherence No of respondents (%)∗
To protect my unborn child 71 (51.8)
To stay healthy and alive 29 (21.2)
As I was told by counselors 27 (19.7)
Informed by my previous
PMTCT experience 16 (11.7)
∗No of respondents greater than 137 because of multiple responses.
Table 4: Reasons for missing drugs among the 33 respondents that
had less than 95% adherence.
Reason for nonadherence No of respondents (%)∗
Forgetfulness 19 (57.6)
Slept oﬀ 11 (33.3)
Work schedule 13 (39.4)
Religious activity 9 (27.3)
Food requirement of the drug 7 (21.2)
Afraid of someone identifying
my drug as HIV drugs 21 (63.6)
∗No of respondents greater than 33 because of multiple responses.
potential confounders, only HIV status disclosure (odds
ratios: 6.1; CI: 2.8–11.6) and having a treatment partner
(odds ratios: 2.5; CI: 1.3–6.7) retained their association with
good adherence.
4. Discussion
Eﬀective strategies to reduce mother-to-child transmission
of HIV infection are well known and well established [1, 3].
TheseincludetheuseofARVdrugs,avoidingunplannedand
unwanted pregnancy in HIV-positive women, safe delivery
and infant feeding options, reduction of unwarranted and
unnecessary surgical intervention during pregnancy and
labor, prevention of prolonged rupture of membrane, and
so forth [1, 3]. Research has also shown that at undetectable
viral load, it is possible to achieve zero mother to child
transmission of HIV infection [1]. Antiretroviral drugs can
only achieve the required eﬀe c ta ta d h e r e n c el e v e lo fa tl e a s t
95% [14]. Poor adherence to antiretroviral drugs has been
reported to be the major challenge to achieving the goal of
antiretroviral therapy [15]. Many factors have been cited as
reasonsfornonadherence inHIV-positive adults [10–12,15–
18], but relatively few adherence studies have been done in
HIV positive pregnant women [4, 19]. Apart from factors
preventing adherence in nonpregnant adults, the nausea and
vomiting of pregnancy and possible eﬀect of the drugs on
the fetus are additional factors that makes adherence in
pregnancy a challenge.
We conducted this study not only to provide this scarce
information on adherence in pregnancy but also to generate
information that will assist during adherence counseling
for pregnant HIV positive women accessing PMTCT ser-
vices.
The nonadherence rate of 19.4% among our cohort,
though comparable to 21.7% reported by Igwegbe et al.
i nS o u t hE a s t e r nN i g e r i ai sm u c hl o w e rt h a n3 7 . 1 %a n d
37.4% reported by Olowookere et al. [10] and Shaahu et al.
[11], respectively, from Southwestern Nigeria where present
study was conducted. Considering that our study and that
of Igwegbe et al. [4] was among pregnant women unlike
the two studies by Olowookere et al. [10] and Shaahu et
al. [11], it seems that adherence is better in pregnancy. It
is not surprising that women are willing and ready to do
anything, to ensure the wellbeing of their oﬀspring. The
above statement was conﬁrmed in this study in which 51.8%
of the adherent women gave the reason of protecting their
unborn child from HIV infection as the major motivator
for taking their drug as prescribed. The eﬀect of vomiting
and nausea of pregnancy was not noticed in this study,
as majority of the women are referred patients after HIV
diagnosis. At the time, these women present to NIMR HIV
treatment centre, the nausea and vomiting of pregnancy
would have subsided.
T h ef r e es e r v i c e so ﬀered at NIMR, compared to other
centres, may have played a great role, as cost of drugs and
laboratory services have been shown to be a major barrier
to antiretroviral drug adherence [18, 20]. The adherence
rate of 99% reported by Jones and Barthlomew [19]a m o n g
194 pregnant women where services were completely free
g i v e sc r e d e n c et ot h i sa s s e r t i o n .T h ea d h e r e n c el e v e lo f9 9 %
reported above also showed that we need to do a lot of work
on issues of adherence. Presently, all patients are counseled
prior to the initiation of antiretroviral therapy, but there
is need to reevaluate counseling methods and techniquesJournal of Pregnancy 5
Table 5: Factors associated with good adherence among the respondents.
Factors Adherent respondents (%)
N = 137
Nonadherent respondents
(%) N = 33 OR (95% CI) P value
Age (years)
(i) <20 2 (1.5) 0 1.00
(ii) 20–35 123 (89.8) 28 (84.9) 1.00
(iii) ≥35 12 (8.8) 5 (15.1) 2.56 (0.85–7.85) 0.08
Number of living children
(i) 0 42 (30.7) 9 (27.3) 0.82 (0.28–2.44) 0.88
(ii) 1–2 57 (41.6) 10 (30.3) 1.00
(iii) >2 38 (27.7) 14 (42.4) 2.10 (0.78–5.75) 0.17
Marital status
(i) Married 119 (86.9) 12 (36.4) (1.13–6.79) 0.23
(ii) Not married 18 (13.1) 21 (63.6) 1.00
Occupation
(i) Unemployed 28 (20.4) 12 (36.4) 1.00
(ii) Employed/Working 109 (79.6) 21 (63.6) 0.45 (0.18–1.11) 0.09
Educational level
completed
(i) Less than secondary 26 (19.0) 6 (18.2) 1.00
(ii) At least Secondary 111 (81.0) 27 (81.8) 1.05 (0.36–3.18) 0.89
HIV status disclosure
(i) Disclosed 131 (95.6) 16 (48.5) (3.06–23.6) 0.000
(ii) Not disclosed 6 (4.4) 17 (51.5) 1.00
Previous PMTCT
experience
(i) Yes 31 (22.6) 3 (9.0) 2.92 (0.78–12.92) 0.13
(ii) No 106 (77.4) 30 (91.0) 1.00
Knowledge of HIV and
ART
(i) Good 124 (90.5) 22 (66.7) 4.77 (1.73–13.22) 0.001
(ii) Poor 13 (9.5) 11 (33.3) 1.00
Has treatment supporter
Yes 85 (62.0) 10 (30.3) 3.76 (1.55–9.26) 0.002
No 52 (38.0) 23 (69.7) 1.00
where necessary, aiming to achieve the 99% adherence level
reported by Jones and Barthlomew [19].
Encouraging the women to come along with a treatment
supporter for the counseling sessions prior to initiation of
antiretroviral therapy preferably the partners would help in
educating the partners appropriately and improving adher-
ence in the long run.
Apart from reviewing the counseling techniques, the
knowledge of the adherence counselors also needs to be eval-
uated as their beliefs and attitudes are central to eﬀective
counseling.
Among the nonadherent women, similar reasons report-
ed in other studies for missing drugs were found [4, 10,
11, 18]. It, therefore, shows that pregnancy related factors
are not the reasons for missing antiretroviral drugs during
pregnancy, but as a result of other personal and sociocultural
factors. Stigma and discrimination remain an important
factor militating against quality HIV care, as 63.6% of
women in this study expressed the reason for missing their
drugs as afraid of being identiﬁed as HIV positive. There
is, therefore, the need for continued campaign against stig-
ma and discrimination if we must improve adherence to
antiretroviraldrugsanduptakeofotherHIV-relatedservices.
The ﬁndings of HIV status disclosure and having a
treatment support as factors associated with good adherence
after controlling for potential confounders is in agreement
with previous studies [8]. With the disclosure of HIV status
to partners, who in most cases is the husband, he will not
only provide support but will act as treatment partner for
thespouse.We,therefore,needtoencouragethesewomen,to
disclose their status to get the maximal beneﬁt of disclosure.
It is important, however, to note that women should not be
forced to disclose their status, as HIV status disclosure has
been reported to be accompanied by partner violence [21].6 Journal of Pregnancy
Instead women who decline to disclose should be counseled
and encouraged until they feel safe to disclose.
It is important to state that self-report used to measure
adherence is not the gold standard for adherence measure-
ment, but it has been reported to be suﬃcient enough to
assess adherence when pill count is not possible and elec-
tronic devices and blood ARV blood measurement are not
feasible [15].
5. Conclusion
In conclusion, this study has shown that good adherence is
achievable during pregnancy, however, more has to be done
to achieve adherence rate of 99% reported elsewhere. The
identiﬁed reasons for nonadherence and the eﬀects of status
disclosure and having a treatment partner will be used to
improve adherence counseling process.
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